ROLF A. STREULI, M.D.; JOHN E. ULTMANN, M.D.
This content is PDF only. Please click on the PDF icon to access.
Sixteen years ago the first patients with advanced Hodgkin's disease were treated with the four-drug chemotherapy regimen MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) at the National Cancer Institute of the National Institutes of Health. In this month's issue, DeVita and coworkers (1) give account of the long-term follow-up of the patients treated with this combination. The introduction of MOPP into the armamentarium against Hodgkin's disease was a breakthrough that changed the prognosis from an inevitably fatal outcome for advanced stages of this disease to good chances of cure in many cases.
What led to the selection of the four-drug regimen
STREULI RA, ULTMANN JE. The Cure of Disseminated Hodgkin's Disease: Prospects and Problems. Ann Intern Med. ;92:693–695. doi: 10.7326/0003-4819-92-5-693
Download citation file:
Published: Ann Intern Med. 1980;92(5):693-695.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use